生物学衰老与遗传易感性联合有助于识别静脉血栓栓塞高危人群:394041名参与者的前瞻性队列研究
该前瞻性队列研究纳入英国生物银行394041人,分析表型年龄加速(PhenoAgeAccel)与静脉血栓栓塞(VTE)的关系,并联合遗传易感性进行风险分层。结果显示PhenoAgeAccel与VTE、深静脉血栓和肺栓塞风险升高相关,且与遗传易感性存在显著相加交互作用。
要点
- PhenoAgeAccel与VTE风险升高相关(HR 1.37,95%CI 1.32-1.42)。
- 生物学衰老且高遗传风险者VTE风险为生物学年轻且低遗传风险者的3.83倍(95%CI 3.51-4.18)。
- PhenoAgeAccel介导了癌症与VTE关联约6%、肥胖与VTE关联约20%。
核心结论
- PhenoAgeAccel与VTE风险升高显著相关,可与遗传风险联合改善VTE风险分层。
- PhenoAgeAccel有望作为临床生物标志物指导VTE的靶向预防和治疗策略。
研究设计与样本
- 前瞻性队列研究,纳入英国生物银行394041名参与者。
- 基于实际年龄和临床生物标志物计算表型年龄,PhenoAgeAccel为表型年龄对实际年龄线性回归的残差。
主要发现
- PhenoAgeAccel与VTE风险升高相关(HR 1.37,95%CI 1.32-1.42)。
- PhenoAgeAccel与深静脉血栓风险升高相关(HR 1.35,95%CI 1.29-1.42)。
- PhenoAgeAccel与肺栓塞风险升高相关(HR 1.41,95%CI 1.34-1.48)。
- PhenoAgeAccel与遗传易感性存在显著相加交互作用。
- 生物学衰老且高遗传风险者较生物学年轻且低遗传风险者,VTE风险为3.83倍(95%CI 3.51-4.18),深静脉血栓风险为3.59倍(95%CI 3.21-4.03),肺栓塞风险为4.39倍(95%CI 3.88-4.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phenotypic age acceleration (PhenoAgeAccel) is a novel clinical aging indicator. This study was carried out to investigate the relationship between PhenoAgeAccel and the incidence of VTE, as well as to integrate PhenoAgeAccel with genetic susceptibility to improve risk stratification of VTE. The study included 394 041 individuals from the UK Biobank. Phenotypic age was calculated based on actual age and clinical biomarkers. PhenoAgeAccel presents the residual obtained from a linear regression of phenotypic age against actual age, reflecting the rate of aging. Significant associations were observed between PhenoAgeAccel and higher risk of VTE (Hazard ratio [HR] 1.37, 95% CI: 1.32-1.42), deep vein thrombosis (DVT, HR 1.35, 95% CI: 1.29-1.42), and PE (pulmonary embolism, HR 1.41, 95% CI: 1.34-1.48) in the findings. PhenoAgeAccel exhibited a significant additive interaction with genetic susceptibility. Biologically older participants with high genetic risk have a 3.83 (95% CI: 3.51-4.18) folds risk of VTE, a 3.59 (95% CI: 3.21-4.03) folds risk of DVT, and 4.39 (95% CI: 3.88-4.98) folds risk of PE, in comparison to biologically younger participants with low genetic risk. Mediation analyses indicated that PhenoAgeAccel mediated approximately 6% of the association between cancer and VTE, and about 20% of the association between obesity and VTE. Our study indicated that PhenoAgeAccel is significantly associated with higher risk of VTE, and can be combined with genetic risk to improve VTE risk stratification. Additionally, PhenoAgeAccel holds promise as a clinical biomarker for guiding targeted prevention and treatment strategies for VTE.
引用
- Hu Z, Xu J, Shen R, et al. Combination of Biological Aging and Genetic Susceptibility Helps Identifying At-Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants. Am J Hematol. 2025. PMID: 39840850. doi:10.1002/ajh.27605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。